|Main uses||Squamous-cell cancer of the lung|
|Side effects||Rash, low magnesium|
|Typical dose||800 mg|
|Elimination half-life||~14 days|
|Chemical and physical data|
|Molar mass||144844.87 g·mol−1|
Necitumumab, sold under the brand name Portrazza, is a medication used for non-small-cell lung carcinoma (NSCLC). Specifically it is used, together with gemcitabine and cisplatin, for squamous-cell cancer of the lung that has spread. Such use; however, is not recommended in the United Kingdom. It is given by gradual injection into a vein.
Common side effects include rash and low magnesium. Other side effects may include cardiac arrest and blood clots. Use in pregnancy may harm the baby. It is a monoclonal antibody that binds to epidermal growth factor receptor (EGFR).
Necitumumab was approved for medical use in the United States in 2015. While it was approved for use in Europe in 2016, this approval was subsequently withdrawn. In the United Kingdom it cost the NHS £1,450 per dose as of 2021. This amount in the United States costs about 4,500 USD.
The typical dose is 800 mg on day 1 and 8 out of 21 days.
- "Necitumumab Monograph for Professionals". Drugs.com. Archived from the original on 4 March 2021. Retrieved 12 November 2021.
- "DailyMed - PORTRAZZA- necitumumab solution". dailymed.nlm.nih.gov. Archived from the original on 9 August 2021. Retrieved 12 November 2021.
- BNF 81: March-September 2021. BMJ Group and the Pharmaceutical Press. 2021. p. 920. ISBN 978-0857114105.
- "Portrazza". Archived from the original on 7 August 2021. Retrieved 12 November 2021.
- "Portrazza Prices, Coupons & Patient Assistance Programs". Drugs.com. Archived from the original on 26 February 2021. Retrieved 12 November 2021.
- "Portrazza: Highlights of Prescribing Information" (PDF). www.accessdata.fda.gov. 2015. Archived (PDF) from the original on 2020-09-30. Retrieved 2019-09-28.
- Hand L (3 March 2015). "Necitumumab Fails in NSCLC". MedScape. Archived from the original on 2015-11-29. Retrieved 2015-11-25.